Comparison of a PNA clamp PCR and an ARMS/Scorpion PCR assay for the detection of K-ras mutations

Diagnostic Molecular Pathology

Volumn 21, Issue 1, 2012, Pages 9-13

  Nordgård, Oddmund ^a   Oltedal, Satu ^a   Janssen, Emiel A M ^a   Gilje, Bjørnar ^a   Kørner, Hartwig ^a,b   Tjensvoll, Kjersti ^a   Smaaland, Rune ^a,b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

ARMS Scorpion; K ras mutations; mutation detection; PNA clamp PCR

Indexed keywords

DNA; PEPTIDE NUCLEIC ACID;

ALLELE; AMPLIFICATION REFRACTORY MUTATION SYSTEM POLYMERASE CHAIN REACTION ASSAY; ARTICLE; CODON; COLON CARCINOMA; GENE MUTATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; METASTASIS; ONCOGENE K RAS; PEPTIDE NUCLEIC ACID CLAMP POLYMERASE CHAIN REACTION ASSAY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADENOCARCINOMA; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENE AMPLIFICATION; HUMANS; PEPTIDE NUCLEIC ACIDS; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84857233589     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31821e59dc     Document Type: Article

References (23)

1. Capon DJ, Seeburg PH, McGrath JP, et al. Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature. 1983;304:507-513. (Pubitemid 13026946)
2. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor. J Clin Oncol. 2009;27:2091-2096.
3. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptortargeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101:1308-1324.
4. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.
5. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19:508-515. (Pubitemid 351325672)
6. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230-3237. (Pubitemid 47325606)
7. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007;96: 1166-1169. (Pubitemid 46625066)
8. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643-2648. (Pubitemid 46548951)
9. Angulo B, Garcia-Garcia E, Martinez R, et al. A commercial realtime PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn. 2010;12:292-299.
10. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374-379. (Pubitemid 351171687)
11. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-1417.
12. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663-671.
13. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
14. Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17:2503-2516. (Pubitemid 19103235)
15. Orum H, Nielsen PE, Egholm M, et al. Single base pair mutation analysis by PNA directed PCR clamping. Nucleic Acids Res. 1993; 21:5332-5336. (Pubitemid 23348594)
16. Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010;16:790-799.
17. Oltedal S, Aasprong O, Møller J, et al. Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy. Int J Col Dis. 2011. In press.
18. Whitcombe D, Theaker J, Guy SP, et al. Detection of PCR products using self-probing amplicons and fluorescence. Nat Biotechnol. 1999;17:804-807. (Pubitemid 29365111)
19. Gilje B, Heikkila R, Oltedal S, et al. High-fidelity DNA polymerase enhances the sensitivity of a peptide nucleic acid clamp PCR assay for K-ras mutations. J Mol Diagn. 2008;10:325-331. (Pubitemid 352019118)
20. Oltedal S, Gilje B, Kørner H, et al. Detection of occult metastases in sentinel lymph nodes from colon cancer patients by K-ras mutation peptide nucleic acid clamp PCR. Ann Surg. 2010;251:1087-1091.
21. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611-622.
22. Weichert W, Schewe C, Lehmann A, et al. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn. 2010;12:35-42.
23. Franklin WA, Haney J, Sugita M, et al. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn. 2010;12:43-50.